Elizabeth Roper
Partner @ Epidarex Capital
Edinburgh, United Kingdom
Elizabeth Roper is a seed investor at Epidarex Capital in Edinburgh focused on Biotechnology and Therapeutics. Elizabeth Roper is based out of Edinburgh, Edinburgh and is the Managing Partner of Epidarex Capital. Elizabeth previously worked at Chroma Therapeutics as a Director of Business Development. Elizabeth Roper attended University College Cork.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Elizabeth Roper invests in
Stages Elizabeth Roper invests in
Countries Elizabeth Roper invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Therapeutics 3 (43%)
- Health Care 2 (29%)
- Medical 1 (14%)
- Pharmaceutical 1 (14%)
Stage
- Seed 3 (43%)
- Series A 3 (43%)
Country
- United Kingdom 4 (57%)
- The Netherlands 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding. | $58M / Series A / Oct 06, 2026 | ||
| Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism. | $8.5M / Seed / Apr 07, 2022 | ||
| Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies. | $24M / Series A / Nov 02, 2021 | ||
| Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours. | $5.9M / Seed / Jul 29, 2021 | ||
| Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies. | Seed / Mar 23, 2021 | ||
| Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours. | $4M / Seed / Jul 14, 2020 | ||
| AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effectsof high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma. | $10M / Series A / Jun 21, 2018 |
Co-Investors
About Epidarex Capital
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, international corporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Epidarex Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Elizabeth Roper
Partner
|
|||
Peter Finan
Partner
|
|||
Terri Burke
Venture Partner
|
|||
|
Kyparissia Sirinakis
Founder & Managing Partner
|
|||
|
Sinclair Dunlop
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Elizabeth Roper invest in?
Elizabeth Roper invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Elizabeth Roper?
Public channels for Elizabeth Roper include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Elizabeth Roper last invest?
The most recent investment recorded for Elizabeth Roper closed in Oct 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
